Royalty Pharma plc stock forecast: up to 36.85 USD RPRX stock price prognosis
Forecast for Thu 18 May 2023 price
Royalty Pharma plc stock price forecast for further price development up to 5.87% (time horizon: 1 day) and price target of 36.85 USD. Positive news sentiment. Short-term (time horizon: 2 weeks) Royalty Pharma plc share price prediction for 2023-05-18 with daily closed price projections
News <--> Close correlation for next day influence (0.05)
Earnings per share
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
Summerized Form 10-K with GPT-2
We deployed $2.3 billion of cash in 2020 for royalties and related assets. We deployed $2.3 billion of cash in 2020 for new royalties and related assets. 7We conduct extensive due diligence when evaluating potential new opportunities. Our right to receive royalties is perpetual. We estimate that our royalties will substantially end in 2033. We added IDHIFA to our portfolio in June 2020. We added Tazverik to our portfolio in November 2019. Therefore, competition to acquire such assets is intense. The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product's commercial life cannot be predicted. We believe that the Manager's relations with its employees are satisfactory. Our Internet site is www.royaltypharma.com. As a result, we may not be able to continue to grow as we have in the past, or at all. Our business is subject to interest rate and foreign exchange risk. This could negatively impact our results of operation for a given period. 24Marketers of products that generate our royalties are outside of our control. Such reports and disclosures may become publicly available. However, there is no assurance that we would be able to raise cash by these means. This is known as the "residency test." We are a public limited company incorporated under the laws of England and Wales. Any such ordinary shares are evidenced by a receipt issued by the depositary. Such changes could adversely affect our financial condition and results of operations. 45Legal claims and proceedings could adversely affect our business.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 60.76/100
Not in ideal financial position.
Historical view, profit is growing.
Company revenue is not growing faster compared with the
Stock price is under book price value.
Insider trading for Royalty Pharma plc
Coyne Terrance P.
Lloyd George W.
Reddoch James F.
Avara Management Ltd
Gg 1978 Sicaf Sif S.a.
Mgg Strategic Sicaf Sif S.a.
Assets / Liabilities
Bollinger Bollinger Bands for Royalty Pharma plc can provide the information where the market is moving based on price information.
Royalty Pharma plc Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
Converting prices to returns Royalty Pharma plc.
On-Balance Volume information for Royalty Pharma plc. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for Royalty Pharma plc. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for Royalty Pharma plc. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for Royalty Pharma plc. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for Royalty Pharma plc. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for Royalty Pharma plc. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for Royalty Pharma plc. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.